AI Assistant
Blog
Pricing
Log In
Sign Up
Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal
Details
Cite
Export
Add to List
The content you want is available to Zendy users.
Already have an account? Click
here.
to sign in.
